Showing 120 of 120on this page. Filters & sort apply to loaded results; URL updates for sharing.120 of 120 on this page
Real-world experience of patients with multiple myeloma receiving ide ...
Ide-cel CAR T-cell construct and mechanism. Based on Friedman et al ...
Full article: BCMA CAR-T cells in multiple myeloma–ready for take-off?
Overview of idecabtagene vicleucel therapy. Insert, ide-cel CAR design ...
NEJM 3期研究新鲜出炉！Ide-cel治疗复发性和难治性多发性骨髓瘤疗效喜人|多发性骨髓瘤|NEJM|复发性|细胞|-健康界
Frontiers | Ciltacabtagene autoleucel: The second anti-BCMA CAR T-cell ...
NEJM：BCMA靶向CAR-T细胞疗法Idecabtagene Vicleucel（Ide-cel）取得积极结果-MedSci.cn
FDA Panel Gives Thumbs Up to Earlier Use of CAR T-Cell Therapy in ...
(PDF) Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed ...
多发性骨髓瘤新药ABECMA(Idecabtagene Vicleucel，ide-cel)中文说明书|香港济民药业 - 知乎
Idecabtagene vicleucel or ciltacabtagene autoleucel for relapsed or ...
Rafat Abonour, MD, on What Nurses Should Know About the Expanded ...
Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in Japanese ...
(PDF) Real-life experiences with CAR T-cell therapy with idecabtagene ...
全球BCMA CAR-T疗法！百时美施贵宝Abecma(ide-cel)获美国FDA批准：治疗多发性骨髓瘤! - FDA信息专区 - 生物谷
Overall Response Rates Prior to Adjustment for Cilta-cel and Ide-cel ...
NEJM：临床试验表明CAR-T细胞疗法Ide-cel 有望治疗复发的多发性骨髓瘤患者_生物科技_健康一线资讯
骨髓瘤新型CAR-T细胞免疫疗法Iecabtagene Vcleucel(Ide-Cel,BB2121)获优先审评,Claudin18.2临床 ...
Myeloma Patient Outcomes After Treatment with Ide-Cel and BCMA-Targeted ...
TCT-ASTCT-CIBMTR 2023: Idecabtagene Vicleucel (ide-cel) Versus Standard ...
IDECABTAGENE VICLEUCEL (IDE-CEL, BB2121), A BCMA-DIRECTED CAR T ...
Idecabtagene Vicleucel (ide-cel) Chimeric Antigen Receptor T-Cell for ...
(PDF) Phase 2 results of idecabtagene vicleucel (ide-cel, bb2121) in ...
Ide-cel shows promise in triple-class exposed RRMM | Multidisciplinary ...
Idecabtagene Vicleucel (ide-cel) Versus Standard Regimens (SRs) in ...
Radiographical response of extramedullary disease after ide-cel ...
KarMMa-3: Ide-cel in Triple-Class-Exposed RRMM | Int'l Myeloma Fn
Real-life experiences with CAR T-cell therapy with idecabtagene ...
Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma | NEJM
Ide-Cel Shows Real-World Efficacy in CNS Multiple Myeloma
Ide-Cel CAR-T Cell Therapy for Refractory Myeloma | Int'l Myeloma Fn
(PDF) P866: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN ...
Idecabtagene Vicleucel (ide-cel) Versus Standard (std) Regimens in ...
Ide-Cel vs BCMA Therapies: Lower Infection Risk - FAERS Analysis ...
P871: IDECABTAGENE VICLEUCEL (IDE-CEL) IN PATIENTS WITH AN I ...
S195: IDECABTAGENE VICLEUCEL (IDE‐CEL) VS STANDARD REGIMENS IN PATIENTS ...
Ide-Cel Yields High Response Rates in Post-Transplant Myeloma Patients
(PDF) S195: IDECABTAGENE VICLEUCEL (IDE-CEL) VS STANDARD REGIMENS IN ...
Valuable Predictors Identified for Ide-Cel Therapy in Multiple Myeloma ...
2024年4月4日FDA批准CAR-T细胞疗法Abecma(Idecabtagene vicleucel、ide-cel、艾基维仑赛)用于多发 ...
Sequencing Matters: Immunotherapy in Multiple Myeloma
(PDF) T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current ...
Immune Engager Therapies Are Associated with Better Outcomes in Post ...
Ide-Cel Shows Superior Survival in Hard-to-Treat Patients With R/R MM
Differences in Ide-cel and Cilta-cel Outcomes Call for Personalized ...
Ide-cel in Relapsed and Refractory Multiple Myeloma | NEJM
IMS Events
Ide-cel vs standard regimens in triple-class–exposed relapsed and ...
Full article: Matching adjusted indirect comparisons of efficacy ...
Full article: Idecabtagene vicleucel (ide-cel) for the treatment of ...
The Differences between Ide-Cel and Cilta-Cel in Relapsed Myeloma at ...
CAR T-cell therapy for patients with multiple myeloma | BLCTT
Abecma(ide-cel)在功能性高风险骨髓瘤中产生持久反应 | 香港致泰药业
Idecabtagene vicleucel chimeric antigen receptor T-cell therapy for ...
Ide-Cel Effective, Safe for Treatment of Multiple Myeloma in a Real ...
T-Cell-Based Cellular Immunotherapy of Multiple Myeloma: Current ...
Real-World CAR-T Outcomes, Use of Ide-cel, Cilta-cel for Myeloma - YouTube
Ide-Cel Shows 73% Response in Complex Multiple Myeloma Cases - European ...
Severe hypophosphatemia following idecabtagene vicleucel regardless of ...
The clinical outcomes and QoL after treatment with ide-cel in older ...
Mean survival (AUC) at 10 years for patients treated with ide-cel based ...
Efficacy and Safety of Idecabtagene Vicleucel (ide-cel) in Patients ...
EASIX-guided risk stratification for complications and outcome after ...
The impact of sustained undetectable MRD on survival in patients with ...
Ide-cel As a Treatment for Myeloma | Int Myeloma Fn
FDA Removes REMS, Lessens Requirements of Liso-Cel/Ide-Cel in Blood Cancers
Monthly costs of care averages among patients receiving ide-cel in the ...
Impact of bridging therapy (BT) on outcome of relapsed refractory ...
Idecabtagene vicleucel for relapsed and refractory multiple myeloma ...
Ide-cel or Standard Regimens in Relapsed and Refractory Multiple ...
KarMMa-3 Highlights: Ide-Cel vs Standard Regimens in Triple-Class ...
P19: BASELINE CORRELATES OF COMPLETE RESPONSE TO IDECABTAGENE VICLEUCEL ...
Factors to consider when choosing between cilta-cel and ide-cel for R/R ...
Retrospective Data Show Improved Efficacy but Higher Toxicity With ...
MAIC of cilta-cel vs ide-cel in R/R multiple myeloma treated with 2-4 ...
Ide-Cel Demonstrates Durable Responses in Relapsed/Refractory Multiple ...
FDA Grants Priority Review for Ide-Cel CAR T Therapy - HealthTree for ...
Ide-Cel Is Effective, Safe for Patients With R/R Multiple Myeloma and ...
Significant Progress in CAR T-Cell Therapy for Difficult-to-Treat ...
(PDF) Real-World Impact of Bridging Therapy on Outcomes of Ide-cel for ...
Choosing between ide-cel and cilta-cel for the treatment of R/R ...
Ide-CEL CAR T-Cell Therapy Effective in Multiple Myeloma Among Patients ...
Creating Space for Ide-Cel and Finding Sequencing Options in Multiple ...
The recent expanded FDA approval of cilta-cel and ide-cel into earlier ...
(A) PFS and (B) OS KM plots for ide-cel treated population (observed ...
Real-World Analysis Shows Superior Efficacy With Cilta-Cel vs Ide-Cel ...
Study on idecabtagene vicleucel for multiple myeloma | Rashmi Bhatnagar ...
Getting to Know the Abecma (ide-cel) CAR T Therapy - HealthTree for ...
Strong Real-World Outcomes Reported for Ide-Cel in Relapsed or ...
Ide-cel therapy for multiple myeloma with renal impairment | VJHemOnc
CAR T-Cell (CART) Therapy - Healthtips by TeleMe
CRB-401 18-month follow-up: influence of T-cell profile on outcome of ...
Ide-Cel Approved in EU for Relapsed/Refractory Multiple Myeloma
FDA Approves Ide-Cel for Triple-Class Exposed R/R Multiple Myeloma
Retrospective study on the outcomes of patients with myeloma treated ...
Improving Treatment for Recurrent Multiple Myeloma With Ide-Cel CAR T ...
